Kantos

Beclometasone dipropionate / Formoterol fumarate dihydrate, the active ingredient in Kantos, is an inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) combination presented as an inhalation product for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD) in adults, helping to control airway inflammation and improve bronchodilation, thereby reducing symptoms and exacerbations.

GNH USA supplies Kantos as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide.

Kantos is an inhaled corticosteroid/long‑acting β2‑agonist used for long‑term control of airway disease.

- Asthma: maintenance therapy that reduces symptoms, frequency of exacerbations and improves lung function. - Chronic obstructive pulmonary disease (COPD): maintenance therapy that helps to decrease breathlessness, reduce exacerbation risk and support overall respiratory health.

Kantos may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth or throat. - Hoarseness: voice changes due to local irritation. - Throat irritation: discomfort or soreness after inhalation. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Severe allergic reaction: anaphylaxis with rash, swelling or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm, especially at high systemic exposure.

Before prescribing Kantos, clinicians should consider several safety measures.

- Assess disease control: ensure asthma or COPD is not acutely worsening. - Monitor for oral thrush: advise rinsing mouth after each use. - Use a spacer device: reduces oropharyngeal deposition. - Avoid abrupt discontinuation: taper to prevent rebound symptoms. - Review concomitant beta‑blocker therapy: may diminish bronchodilator effect. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Kantos can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may antagonize bronchodilation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic corticosteroid levels. - Diuretics: may enhance hypokalaemia risk when combined with β2‑agonists.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive bronchodilator effect, monitor lung function. - Theophylline: possible increase in plasma concentrations. - Other inhaled corticosteroids: cumulative steroid exposure, assess total dose.